# Evkeeza® (evinacumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/evinacumab

> The FDA approved Evkeeza® (evinacumab), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on Sep 2025 for homozygous familial hypercholesterolemia.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Evkeeza® (evinacumab) |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [homozygous familial hypercholesterolemia](https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### Sep 2025: FDA approval

- Status: completed, approved. Date confidence: month. Indication: homozygous familial hypercholesterolemia.
- First seen 2025-10-28, last confirmed 2025-10-28.
- Press release filed with the SEC (EX-99) (accession 0000872589-25-000026): "•In September 2025, the FDA approved Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH), extending the already approved indication to include children from age 1 to less than 5 years old." https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/evinacumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Evkeeza® (evinacumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/evinacumab

```bibtex
@misc{secapidev_pdufa_evinacumab_20261116,
  title        = {Evkeeza® (evinacumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/evinacumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_evinacumab_20261116","title":"Evkeeza® (evinacumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/evinacumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
